Background: Sub-Saharan Africa carries the highest HIV burden globally. It is important to understand how interventions cost-effectively fit within guidelines and implementation plans, especially in low-and middle-income settings. We reviewed the evidence from economic evaluations of HIV prevention interventions in subSaharan Africa to help inform the allocation of limited resources. Methods: We searched PubMed, Web of Science, Econ-Lit, Embase, and African Index Medicus. We included studies published between January 2009 and December 2018 reporting cost-effectiveness estimates of HIV prevention interventions. We extracted health outcomes and cost-effectiveness ratios (CERs) and evaluated study quality using the CHEERS checklist. Findings: 60 studies met the full inclusion criteria. Prevention of mother-to-child transmission interventions had the lowest median CERs ($1144/HIV infection averted and $191/DALY averted), while pre-exposure prophylaxis interventions had the highest ($13,267/HIA and $799/DALY averted). Structural interventions (partner notification, cash transfer programs) have similar CERs ($3576/HIA and $392/DALY averted) to male circumcision ($2965/HIA) and were more favourable to treatment-as-prevention interventions ($7903/HIA and $890/DALY averted). Most interventions showed increased cost-effectiveness when prioritizing specific target groups based on age and risk. Interpretation: The presented cost-effectiveness information can aid policy makers and other stakeholders as they develop guidelines and programming for HIV prevention plans in resource-constrained settings.
Introduction
Sub-Saharan Africa (SSA) has experienced a large reduction in new HIV infections over the last decade, with the number of incident infections dropping over 30% since 2010 [1] . This decrease in burden reflects the accomplishment of a global effort focused on a region in which approximately 70% of all people living with HIV reside [2, 3] . Despite this success, the decline in incidence is slowing, and gaps in the scale-up of HIV prevention services persist throughout SSA [3] . US$4.5 billion was allocated for HIV prevention investments in 2016 by the international community; however, a recent UNAIDS report stated that an additional annual investment of US$7 billion is urgently needed to meet the 2030 Sustainable Development Goals targets [4] [5] [6] . To improve the efficiency of programming for HIV prevention, optimizing limited financial resources is crucial to scale up highquality, cost-effective interventions to maximize HIV prevention [7] .
In addition to evidence-based prevention tools such as voluntary medical male circumcision (VMMC) and prevention of mother-tochild transmission (PMTCT) strategies, new prevention methods such as HIV pre-exposure prophylaxis (PrEP) have been heralded for their remarkable clinical results in the reduction of HIV transmission. However, it is important for policy-and decision-makers to identify where and how such costly interventions fit within regional and national HIV implementation plans and budgets, particularly in resource-limited countries [8] .
Ascertaining the cost-effectiveness of prevention interventions is necessary for optimal resource allocation and for identifying inefficiencies within prevention programs [7] .
A systematic review of HIV prevention intervention costeffectiveness was published in 2009 by Galarraga et al., which concluded that the number and quality of cost-effectiveness studies were insufficient and too limited at that time to aid decision making and EClinicalMedicine 10 (2019) policy recommendations [9] [10] . However, since 2009, many studies have been published on the cost-effectiveness of various prevention interventions, including newer PrEP technologies and treatment-asprevention [8] .
No systematic review to date has evaluated these newer prevention interventions with a focus on SSA. Such a review would provide important information on HIV prevention costs, outcomes, and effectiveness to support policies and decision-making [8, 9] . The purpose of this review is to systematically review published analyses of the costeffectiveness of HIV prevention interventions in SSA settings. We aim to 1) review evidence from studies published in the last decade that have evaluated cost and outcome metrics for HIV prevention interventions, 2) compare the costs and effects of specific prevention interventions, and 3) understand the assumptions driving cost-effectiveness in order to inform allocation of limited HIV prevention resources.
Methods

Search Strategy and Selection Criteria
We conducted this systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [10] . We searched PubMed/MEDLINE, Web of Science, Econ-Lit, Embase, and African Index Medicus. Additionally, we reviewed reference lists of retrieved articles as well as governmental and organizational reports to complement our search. We limited studies published between January 1, 2009 and December 31, 2018. The following keywords were used: "HIV"; "prevention" or "control"; "cost" or "cost-analysis" or "cost-effectiveness"; "sub-Saharan Africa". The full search strategy, including keywords for each database, can be found in the supplemental material.
Inclusion criteria included full articles that were peer-reviewed and published in English, and reported cost and outcome measures or analysed cost-effectiveness of an HIV prevention intervention. Interventions included, but were not limited to: VMMC, PMTCT, TasP, PrEP, behavioral interventions, vaccinations, and microbicides. As a multipronged strategy, two types of PMTCT interventions were considered: Prong II, interventions to prevent unintended pregnancies of HIVpositive women, and Prong III, interventions providing services to reduce HIV transmission from HIV-positive women to their infants. Geography was limited to country settings within SSA, as defined by the United Nations [11] . A full list of eligible country settings can be found in the supplemental material. Studies that focused on HIV treatment with no prevention aspect, systematic reviews, meta-analyses, conference abstracts, and guideline reports were excluded. Studies assessing cost-effectiveness of an intervention's combined impact for both HIVpositive and HIV-negative persons and studies that did not describe costing analyses and effectiveness measures were excluded. Two reviewers aggregated a list of articles produced by the database search and conducted independent screenings based on title and abstract. All discrepancies were resolved by a third reviewer.
Quality Assessment and Data Extraction
Two reviewers independently extracted data from each of the selected studies using a prepared data form, and an independent crosscheck by a third reviewer was conducted to identify and resolve any disagreements or uncertainties. We developed the data form using guidance from Emory colleagues and prior systematic reviews on similar topics. We assessed the quality of studies using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, which contains a 24-point checklist to assess economic evaluation studies [12] .
We extracted data on intervention type, study design or model type, geographic setting, HIV transmission method, population, intervention description, perspective, and time horizon. Additional extracted information included scenario descriptions, intervention effectiveness, cost-effectiveness metric results, and discounting rates for effects and costs. We categorized studies by prevention intervention type to compare intervention-specific results. The primary measures of interest were cost per HIV infection averted (HIA), cost per disability-adjusted life year (DALY) averted, cost per quality-adjusted life year (QALY) gained, and cost per life year gained (LYG). We converted study costeffectiveness results to 2018 US$ using the Consumer Price Index
Research in context
Evidence Before This Study
There is an increasing interest in cost-effectiveness of HIV programming among stakeholders. The last systematic review on the cost-effectiveness of all HIV prevention interventions was published nearly ten years ago. At that time, cost-effectiveness studies were limited and often unavailable for specific interventions. A 2013 systematic review presented evidence from studies specifically on pre-exposure prophylaxis and concluded that the intervention's impact relied highly on contextual assumptions. In the past decade, an increasing number of cost-effectiveness studies in HIV prevention literature have become available, but there has not yet been a single review that synthesizes the evidence from all of these studies. We conducted a systematic review for cost-effectiveness studies on HIV prevention interventions. We searched PubMed/MEDLINE, Web of Science, Econ-Lit, Embase, and African Index Medicus, for studies published between January 1, 2009 and December 31, 2018. Search terms included "HIV", "prevention" or "control"; "sub-Saharan Africa"; "cost" or "cost-effectiveness".
Added Value of This Study
This is the first review that provides a comprehensive and update look at the cost-effectiveness of all HIV prevention interventions targeted towards HIV-individuals. Additionally, this review focuses solely on sub-Saharan Africa, the region that carries the vast majority of the global disease burden. We show that voluntary medical male circumcision (VMMC) and prevention of mother-to-child transmission (PMTCT) interventions are costeffective in almost all contexts. We provide evidence of costeffectiveness of other newer biomedical interventions, including pre-exposure prophylaxis (PrEP) and treatment as prevention (TasP). We hope that the evidence from this review will aid various stakeholders, including Ministries of Health, program implementers, and international donors, in their decision-making regarding resource allocation policy for HIV prevention.
Implications of All the Available Evidence
The number of studies included in this review reflects the increasing importance of considering cost-effectiveness when designing or implementing HIV prevention programs in subSaharan Africa. Numerous studies focused on new biomedical interventions, and many of these studies used mathematical modeling to provide evidence of these interventions' cost-effectiveness since they have not yet been scaled up in sub-Saharan Africa. However, this review shows that most interventions can be cost-effective in specific contexts. As such, we encourage others to use the results of this review with caution. Future economic and costing studies on HIV prevention should include more realistic scenarios so that these data are more accessible and relevant to policymakers and other stakeholders.
(CPI) Inflation Calculator and compared them to the International Monetary Fund 2018 estimates of gross domestic product (GDP) per capita for each study setting [13, 14] .
For each intervention type, we calculated median CERs. Separate medians were calculated for studies reporting cost per HIA estimates and studies reporting cost per DALY averted, QALY gained, or LYG. For studies that explored more than one geographic setting, we considered results from the different settings as individual estimates if they were reported as such within a single study; these results were considered separately when we calculated median CERs.
Results
We identified and screened 1115 articles, of which 146 met criteria to be assessed for eligibility. The 969 articles that were initially excluded were deemed ineligible based on the article title and abstract and did not meet either the geographic setting or intervention criteria. Out of the 146 articles, 60 met the full inclusion criteria (Fig. 1) . These 60 peer-reviewed studies provided cost-effectiveness results for the following HIV prevention interventions: 14 studies on VMMC, 13 studies on PrEP, five studies on TasP, 15 studies on PMTCT, nine studies on other biomedical interventions, one study on behaviour change, and three studies on structural interventions . Among PMTCT studies, 14 considered Prong III strategies, while one focused on Prong II. Table 1 describes characteristics of each study, including study design or model type, geographic setting, method of transmission, target population, time horizon, HIV prevalence of the target population, perspective, and description of the intervention assessed. Studies focused on heterosexual transmission among the general population except for studies exploring prevention of mother-to-child-transmission. Costs were predominately assessed through a healthcare payer perspective. Two studies included results from countries outside of SSA; non-SSA results were excluded from this review [56, 62] .
We extracted and converted each study's reported costeffectiveness measure and converted them to 2018 US$. Table 2 describes these measures. Most studies provided discounted results, with discounting ranging from 0%-5% for the base case scenario, as is standard in cost-effectiveness literature [37] . Outcome measures were presented as number of HIV infections averted (HIA) for a specific scenario, with fewer studies reporting quality-adjusted life years (QALYs) gained or disability-adjusted life years (DALYs) averted. A number of studies did not provide numerical values for cost-effectiveness measures but rather stated whether an intervention was a dominant (cost-savings with better outcomes) or dominated (costlier with poorer outcomes) strategy [55, 58, 67] . The most cost-effective interventions included -$8356 per HIA for a microbicide intervention in South Africa, − $312 per HIA for a PMTCT intervention in Malawi, and $470 per HIA for a VMMC intervention in Uganda [18, 49, 62] .
The Table 3 and Fig. 8 provide the results of the quality assessment of each study using the CHEERS checklist.
Discussion
This review summarizes the evidence to date on recent studies of the cost-effectiveness of HIV prevention interventions and serves as an SSAspecific update to the 2009 review by Galarraga et al. [9] Results from this review illustrate that established interventions, such as VMMC and PMTCT, remain cost-effective, as previously found in the 2009
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Studies included (n = 60) Fig. 1 . Flowchart diagram for study selection. review. For newer prevention strategies, such as PrEP and TasP, many of the studies relied on various assumptions and scenarios that may not reflect reality. The review found that PMTCT and VMMC interventions were the most cost-effective. Studies on PMTCT interventions, including HAART, infant feeding methods, expedited ART, and Option B + suggest that these strategies are very cost-effective [47, 49, 50, 54, 56, 57, 59] . These studies provide evidence supporting WHO guidelines of transitioning from Option A and of recommending PMTCT Option B and Option B+. When WHO began the policy transition from Option B to Option B + in 2013, the agency conducted a preliminary cost analysis to estimate the incremental cost of switching to the new policy [75] . The authors argued that researchers should develop additional cost-effectiveness models to appropriately evaluate the cost of the policy with programmatic data. A number of studies have since provided evidence supporting the policy decisions around Option B + [56, 57] . However, stakeholders should be mindful that implementation of strategies like Option B + raises concerns since many of these studies do not take into account initial costs and upfront investment required to scale up PMTCT programs to a level that can be considered cost-effective over an extended time period [61, 75] . Additionally, while the majority of PMTCT studies included in this review focused on Prong III, only one study addressed PMTCT Prong II by studying the expansion of family planning services as a cost-effective method to avert HIV infections through the prevention of unintended pregnancies [47] . This focus may reflect recent programmatic shifts towards PMTCT Prong III and treatment of HIV infected women, even though family planning is effective in reducing MTCT.
The VMMC studies included in this review agreed that the intervention was cost-effective. Seven different studies developed models that estimated cost effectiveness of VMMC at 80% coverage, which is a common target for many HIV prevention programs; however, achieving this level of coverage is often not feasible in many settings [16, 19, [23] [24] [25] [26] [27] . Additional studies exploring cost effectiveness at various levels of VMMC coverage may help inform decision makers in areas where 80% coverage would be difficult to attain. Multiple studies explored scenarios targeting VMMC at different age groups, with a consensus that prioritizing younger males is more favourable and cost-saving compared to targeting the general male adult population [15, 22, 24] .
Similarly, a common conclusion was that PrEP strategies targeting specific risk groups were more cost-effective than general PrEP strategies [29, 32, 34, 35, 39] . Four studies found that PrEP was most costeffective when using a prioritization strategy aimed at young individuals who are most at-risk, including having more than four partners and reporting low condom use [32, 34, 39, 41] . The majority of included PrEP studies were set in South Africa, a country that could perhaps better absorb the higher costs of PrEP implementation compared with others in the region. However, three studies in Zambia and Mozambique agreed that prioritizing high-risk individuals would create the most effective scenario for PrEP implementation, adding to the evidence that a targeted PrEP strategy could be feasible across country settings [32, 35, 36] .
The assumption of 100% PrEP coverage considered in many studies may be difficult to implement [11, 14] . This scenario implies that every eligible individual would receive PrEP, which may not be realistic in settings where universal treatment has not even been realized. Many studies point out that achieving such a high level of PrEP coverage would be less cost-effective than simply increasing ART coverage. Accordingly, WHO issued recommendations in 2015 to provide PrEP as a prevention option to individuals at substantial risk of acquiring HIV in settings with high HIV incidence [76] . Although studies have shown that PrEP can be cost-effective when targeted towards high-risk groups and when assuming high adherence, it remains a challenging intervention due to high costs, ethical issues, and inequitable distribution [8] .
The five studies included in this review were not in agreement with regard to the cost-effectiveness or the feasibility of TasP strategy; one study concluded that TasP was less cost-effective than a combination of VMMC and ART, which is already the standard practice in many subSaharan African settings [42] . From this review, it is unclear whether or not TasP would be more cost-effective in certain settings over others. Despite this uncertainty, many countries have already developed and implemented guidelines for TasP and universal test-and-treat (UTT) Fig. 3 . Cost-effectiveness measures of PrEP interventions. Data points reflect the measures from PrEP studies reporting cost per HIV infection averted (above) and cost per DALY averted or QALY gained (below). Points represent study-specific cost-effectiveness estimates; error bars represent estimate ranges, if provided in study results. [77] . Healthcare investment to provide UTT services successfully is substantial, especially in extensive resource-constrained settings [78] .
This review also included studies that explored cost-effectiveness of methods that are still in development and not currently available on the market, including long-acting PrEP injections, HIV vaccines, and microbicide gels. The findings from these studies suggest that these interventions would be cost-effective once accessible [62] [63] [64] 66, 68, 69] . Only one study included in this review considered the reduction of HIV incidence by estimating the intervention effect of schistosomiasis treatment. Mbah et al. showed that mass praziquantel administration would be a cost-effective approach to reduce HIV transmission. In addition to its affordability, praziquantel treatment is very safe, well tolerated, and easily administered, but it has not been explicitly considered as a HIV prevention intervention, as the link between HIV acquisition and schistosomiasis remains unclear [65] .
The vast majority of the included studies determined costeffectiveness based on the WHO-CHOICE guidance that considers interventions to cost-effective if the cost per DALY averted is between one and three times the study country's GDP per capita [79] . This threshold is becoming increasingly contested, as many experts believe that it does not consider governments' ability to generate the appropriate resources or willingness to pay [80, 81] . Some studies have translated HIA to DALYs; we did not find a standard conversion that would be applicable to the various country settings [17] . Moreover, the usefulness of this type of threshold is especially important when discussing high cost interventions, such as PrEP and TasP. Although these prevention strategies may be considered cost-effective under certain assumptions, this may not always translate into feasible implementation. The GDPbased threshold is unrelated to national and donor HIV budgets, both of which are needed to understand an intervention's affordability. Thus, more information is need on whether many SSA countries would be able to implement a large-scale PrEP program, although its use as a main prevention strategy has been heavily emphasized in policy discussion [8] . Many countries are already struggling to provide universal ART, and adding a high-cost strategy may apply further pressure on resource limited prevention programs.
In the 2009 review, Galarraga et al. concluded that not enough information regarding cost-effectiveness of many prevention strategies existed for decision-making or policy change [9] . Their review included many cost-effectiveness studies on interventions for behaviour change, intravenous drug use (IDU) harm reduction, and information, education, and communication. The present review found only two studies on behaviour change and structural interventions, with most recently published studies focusing on biomedical interventions. This shift represents a reflection of changing priorities of the international donor community and emerging technology available from pharmaceutical companies. The authors mentioned the lack of cost-effectiveness studies on vulnerable groups, such as men who have sex with men (MSM) and female sex workers (FSW). Similarly, the current review found only one study focusing on FSWs, although there are published studies on these populations in settings outside of Africa [66, 82] . The continuing dearth of studies on these vulnerable populations in sub-Saharan Africa ought to be addressed by future research, as costing studies can inform policymaking.
Several limitations were recognized while conducting this review. First, behavioral and structural interventions, like partner concurrency reduction and condom use, have historically been included in HIV prevention programs [71] . Although the studies in this paper suggest that these strategies are cost-effective, most analyses do not separate the effect of behaviour change on HIV incidence from other interventions, thus not allowing us to understand the effectiveness of these interventions in isolation [67, 71] . Second, comparability across studies was difficult since parameters, settings, and assumptions vary. Unless studies present cost-effectiveness estimates using the same assumptions, base year, time horizon, and discount rate, we should take caution when comparing study estimates.
Third, many of the cost-effectiveness studies offer evidence for a specific intervention in a number of scenarios, but few address the potential effects of an intervention in scenarios outside the scope of the study. This makes it difficult to generalize a study's results to other country settings, creating an obstacle for policy makers in determining how and when a single intervention is the most cost-effective for a specific country. The limited geographic coverage among the studies additionally does not allow for broad generalizability. South Africa was the setting in 24 of the 60 studies (40%) and just three countries (South Africa, Zambia, and, Malawi) comprise over 60% of the studies. Lastly, this review is not immune to publication bias. Studies that do not demonstrate interventions as cost-effective are less likely to be submitted to peer-reviewed journals or to be published by journals [83] . It is possible that some cost-effectiveness results of current HIV interventions are not available to key policy makers, which poses a large problem. Despite the aforementioned limitations, this review included studies of good quality, highlighting the strength of the available evidence.
The large number of studies included in this review reflects the increasing importance of considering cost-effectiveness as a factor in implementing HIV prevention interventions in sub-Saharan Africa. The studies demonstrated intervention cost-effectiveness under a variety of scenarios and emphasized interventions targeting high-risk populations. In contrast to the 2009 Galarraga review, which concluded that sufficient cost-effectiveness data did not exist to inform large-scale decision making, the results from emergent, more robust and varied costing studies may serve as an aid to inform evidence-based decisions. Key stakeholders, such as international donors and government agencies, should consider cost-effectiveness results and affordability when developing national guidelines and protocols for HIV prevention to maximize prevention impact under resource constraints. However, important gaps in the research persist: a lack of focus on vulnerable populations remains an important concern in this region, and additional studies that discuss the cost-effectiveness of different combinations of interventions are needed to reflect the reality of HIV programs in this region [84] .
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